Intangible Assets

Proprietary Antibody Platform: Genmab's core competitive advantage is its proprietary antibody technology platforms, including DuoBody and HexaBody, which have enabled the development of multiple first-in-class and best-in-class therapies. These platforms are protected by a robust patent portfolio, supporting revenue durability and premium pricing relative to peers.

High-Value Partnerships and Licensing: Genmab has established strategic collaborations with leading pharmaceutical companies such as AbbVie, Janssen (Johnson & Johnson), and Seagen, which validate its technology and provide access to global commercialization channels. These partnerships generate milestone and royalty revenues, reducing dependence on single products and enhancing valuation resilience.

Strong Clinical and Regulatory Track Record: The company has successfully advanced multiple antibody products to late-stage development and regulatory approval, including Darzalex (daratumumab), which has become a standard of care in multiple myeloma. This track record strengthens Genmab's reputation and supports future pipeline monetization.

Genmab's moat is anchored in its proprietary antibody platforms, extensive patent protection, and a proven ability to form high-value partnerships. These intangible assets underpin durable revenue streams and support premium margins versus most biotech peers.

Network Effects

Partner Ecosystem Expansion: Genmab's value increases as more pharmaceutical partners adopt its antibody platforms, but the effect is limited to B2B relationships rather than direct user networks. The incremental value from each new partner is meaningful but not exponential.

Data Accumulation from Clinical Programs: The company benefits from accumulating clinical and real-world data across its partnered and proprietary programs, which can inform future drug development. However, this data advantage is not exclusive and can be replicated by large pharma competitors.

No Direct Patient or Provider Network: Genmab does not operate a direct network of patients or healthcare providers, limiting the scale and defensibility of network effects compared to digital health or platform peers.

While Genmab benefits from a growing partner ecosystem and data accumulation, its network effects are moderate and largely confined to B2B relationships, with limited compounding advantages versus larger pharma peers.

Switching Costs

Embeddedness in Partner Pipelines: Once a pharmaceutical partner integrates Genmab's antibody technology into its pipeline, switching to alternative platforms would entail significant time, cost, and regulatory risk, supporting moderate customer stickiness.

Therapeutic Switching Barriers: For approved products like Darzalex, physicians and patients face moderate switching costs due to established clinical efficacy and safety profiles, but these are not insurmountable if superior alternatives emerge.

Switching costs are moderate, driven by integration into partner pipelines and established clinical use, but remain vulnerable to technological disruption or superior competing therapies.

Cost Advantage

Lean Operating Model: Genmab maintains a lean cost structure by focusing on R&D and leveraging partners for commercialization, which supports above-average returns on invested capital (ROIC TTM: 9.9%) compared to many biotech peers.

No Scale-Based Manufacturing Edge: The company does not own large-scale manufacturing or distribution infrastructure, limiting its ability to achieve cost advantages through scale relative to integrated pharma competitors.

Genmab's cost advantage is moderate, stemming from its focused R&D model and efficient capital allocation, but it lacks the scale-based cost efficiencies of larger, vertically integrated peers.

Efficient Scale

Niche Focus in Antibody Therapeutics: Genmab operates in specialized segments of the antibody therapeutics market, where a limited number of players can profitably compete due to high R&D and regulatory barriers.

Competition from Large Pharma: Despite its niche focus, Genmab faces competition from large pharmaceutical companies with significant resources, which can enter overlapping therapeutic areas and erode market share.

Pipeline Concentration Risk: The company's revenue is concentrated in a few key products and partnerships, increasing exposure to competitive and regulatory risks if new entrants target the same indications.

Genmab benefits from efficient scale in select antibody niches, but faces ongoing competition from larger incumbents and is exposed to concentration risk in its product pipeline.

Overall Score

Genmab possesses a strong economic moat, primarily driven by its proprietary antibody platforms, robust patent portfolio, and high-value partnerships. While network effects and switching costs are moderate, and cost advantages are limited by scale, the company's intangible assets provide durable competitive advantages and support resilient margins. The moat is strong relative to most biotech peers, though not immune to disruption from larger pharma or technological shifts.